What do USP, EP and JP standards mean for pharmaceutical gelatin?

Beyond Biopharma · Pharmaceutical Gelatin FAQ

Short answer: USP, EP and JP are the abbreviated names of the United States Pharmacopeia, the European Pharmacopoeia and the Japanese Pharmacopoeia. Each publishes a monogram on Gelatin that sets out the identity tests, purity limits and analytical methods a gelatin must pass to be acceptable for pharmaceutical use in its region. They cover the same ground — gel strength, viscosity, pH, impurities such as sulphur dioxide, heavy metals and ash, and microbial quality — but details and limits differ slightly between editions. Because gelatin is traded and registered globally, a single product is usually qualified against more than one of these references at once, and the supplier declares which monograph each lot complies with on the certificate of analysis.

What a pharmacopoeia actually is

A pharmacopoeia is an officially recognised reference book of standards for medicines and the materials used to make them. For gelatin, the relevant monograph is a written specification: it says what the material must look like, how it must behave in defined tests, what impurities may be present only up to stated limits, and which methods must be used to check it. Meeting a monograph matters because regulators in that region expect excipients used in medicines to conform to it. USP, EP and JP are three of the most widely cited: they serve the United States, the European region and Japan respectively.

What the gelatin monographs cover

Although the exact wording differs, a typical pharmacopoeia gelatin monograph describes the source and how it was made, then lists measurable properties and limits:

The precise list and the numerical limits are defined by each pharmacopoeia and can be updated between editions, so always work from the current version rather than a summary.

Why USP, EP and JP often appear together

Gelatin is a global commodity and one production lot may end up in medicines sold across many countries. Rather than qualify separately for every market, a supplier commonly claims compliance with several monographs at once so the same material is acceptable to more than one regulator. That is why a certificate will frequently show the lot meets USP and EP, or EP and JP, together. The monographs are broadly aligned but not identical, and where limits differ the supplier must meet the stricter applicable requirement to hold the combined claim.

How compliance is shown, not assumed

“Meets USP” is only meaningful if it is demonstrated. Suppliers back the claim with a certificate of analysis listing the tested parameters, the methods used, the results and the stated limits, all tied to a specific production lot. They also hold the supporting stability, validation and raw-material documentation that a pharma auditor would examine. Buyers should read the COA for the lot, confirm which edition or version of each monograph is cited, and check that the parameters that matter for their own dose form are covered.

Practical guidance for choosing

Which pharmacopoeia matters to you depends on where the finished medicine will be registered. A product filed in one region may only need the corresponding monograph, while a globally distributed product will commonly specify two or more. The safe approach is to confirm the target market’s requirement with the regulatory affairs team, then choose a gelatin whose COA declares compliance with those monographs. When in doubt about whether a specific specification satisfies a local authority, ask that authority or your regulatory consultant directly rather than relying on general summaries.